A population-based database of 55,327 older women with early-stage breast cancer treated during 2000 to -2008 was used to determine trends in local therapies and their associated costs. During this interval, the use of mastectomy in the elderly declined Purpose: Older women with early-stage disease constitute the most rapidly growing breast cancer demographic, yet it is not known which local therapy strategies are most favored by this population in the current era. Understanding utilization trends and cost of local therapy is important for informing the design of bundled payment models as payers migrate away from fee-for-service models. We therefore used the Surveillance, Epidemiology, and End Results Medicare database to determine patterns of care and costs for local therapy among older women with breast cancer. Methods and Materials: Treatment strategy and covariables were determined in 55,327 women age !66 with Tis-T2N0-1M0 breast cancer who underwent local therapy between 2000 and 2008. Trends in local therapy were characterized using Joinpoint. Polychotomous logistic regression determined predictors of local therapy. The
Introduction
Older women with early breast cancer constitute the most rapidly growing breast cancer demographic, with an estimated 114,000 cases annually and a growth forecast of 57% from 2010 to 2030 (1). Historically, the most common local treatments for such women were lumpectomy followed by approximately 6 weeks of external beam radiation or mastectomy without reconstruction. However, recent literature suggests that many older women may be appropriate candidates for either brachytherapy, which conveniently decreases the radiation treatment course to 1 week, or complete omission of any radiation, which confers even more convenience (2) (3) (4) . Despite increasing support for these convenient options for breast conservation, recent patterns of care studies have demonstrated an increasing use of mastectomy in the overall breast cancer population, potentially driven by the greater availability and use of breast reconstruction (5) (6) (7) (8) (9) .
For older women with early breast cancer, it is not known whether the increasing availability of more convenient breast conservation strategies has led overall to an increased use of breast conservation, or whether the increasing availability of breast reconstruction has led to an increased use of mastectomy. Understanding utilization and cost trends in this large and growing population of older women with early breast cancer is critically important for promoting value, defined as the quality of outcomes achieved per dollar spent, as payers migrate away from fee-forservice reimbursement toward bundled care payment models (10) (11) (12) . We therefore used the Surveillance, Epidemiology, and End Results (SEER)-Medicare cohort to characterize population trends in the use of local therapy and to characterize the predictors and cost of local therapy for older women with early breast cancer who are Medicare beneficiaries.
Methods

Data source
The SEER-Medicare database captures clinical, pathologic, and insurance claims data for incident cancers diagnosed in Medicare beneficiaries who reside within 1 of 16 geographic areas that account for 26% of the United States population. The case ascertainment rate is approximately 98% (13) . In this study, the demographic and tumor characteristics for incident malignancies diagnosed from January 1, 2000, to December 31, 2008 , were linked to Medicare treatment claims from January 1, 1999, to December 31, 2010 .
Study sample
From 2000 to 2008, 195 ,217 women age ! 66 years received diagnoses of invasive or in situ breast cancer and reported in the SEER-Medicare cohort. We applied standard exclusions as outlined in Table E1 (available online at www.redjournal.org) to create an analytic cohort of 55,327 patients with early-stage disease (Tis-T2N0-1). We required that all patients maintain fee-for-service Medicare coverage from 12 months before through 24 months after diagnosis to permit ascertainment of comorbid illness before diagnosis and delayed breast reconstruction after diagnosis.
Outcomes
The primary outcome for this study was type of local treatment, defined as 1 of the following: (1) lumpectomy followed by external beam radiation; (2) mastectomy without reconstruction within 2 years of diagnosis; (3) mastectomy with reconstruction within 2 years of diagnosis; (4) lumpectomy followed by brachytherapy; or (5) lumpectomy with no adjuvant radiation therapy. For patients treated with mastectomy, we also required that they did not receive radiation within 12 months of surgery, inasmuch as the use of postmastectomy radiation would likely indicate a more advanced cancer. Type of surgery (lumpectomy vs mastectomy) was determined from both SEER data and Medicare claims within 12 months of diagnosis, with the most extensive surgery coded by either source considered to be the definitive surgery. Patients were considered to have received breast reconstruction if any claim for reconstruction was present within 24 months of diagnosis (Table E2 ; available online at www. redjournal.org).
Baseline covariables
The patient characteristics from the SEER data included age at diagnosis, race, sex, and year of diagnosis. Modified Charlson comorbidity index with Klabunde modification was determined from claims spanning an interval of 12 months to 1 month before diagnosis (14, 15) . Tumor characteristics extracted from SEER included T stage and N stage, grade, histology, estrogen receptor (ER) status, and laterality. Lymphovascular space invasion and margin status are not reported. Area-level characteristics included urban/rural residence, median income, educational attainment, and county-level density of surgeons and radiation oncologists determined from the Area Resource File (16) .
Determination of cost
The costs for each patient were calculated from a payer perspective using all inpatient, outpatient, and carrier claims within 2 years of diagnosis and were divided by calendar month to evaluate trends over time related to date of diagnosis. Costs were adjusted for geographic variation using the geographic adjustment factor for Part A claims and the geographic practice cost index for Part B claims and for inflation using the Prospective Pricing Index for Part A claims and the Medicare Economic Index for Part B claims (17, 18) . Costs were also adjusted for differences in use of chemotherapy by normalizing costs of each local therapy to the utilization rate of chemotherapy in patients treated with lumpectomy plus external beam radiation. All costs are reported in 2014 dollars.
Statistical analysis
The baseline characteristics across treatment strata were compared with Pearson's c 2 test. Trends in treatment utilization by calendar year quarter were determined with Joinpoint linear regression models (Joinpoint version 3.4.3). Adjusted associations between baseline characteristics and treatment strategy were estimated using polychotomous logistic regression. Lumpectomy followed by external beam radiation served as the referent group for this model because it was the most commonly used strategy and its use was relatively stable over time. Covariables were selected for inclusion in this model a priori on the basis of clinical relevance or if associated with the outcome in univariate analysis at P<.20. The model was iteratively refined to optimize fit.
To determine trends in costs, the total median 2-year costs by treatment strategy and year of diagnosis were calculated. Linear regression was used to determine direction and magnitude of cost growth over time. The trend line for lumpectomy and brachytherapy started at 2002 to ensure adequate numbers for meaningful regression; the U.S. Food and Drug Administration (FDA) first approved balloon brachytherapy for breast cancer in 2002.
All statistical tests were 2-sided with P .05 and were conducted with SAS version 9.3 (Cary, NC). Our institutional review board granted this study exempt status.
Results
Baseline characteristics
Of 55,327 women, the median age was 75 years, and 48,792 (88.5%) were white. The number of patients receiving each treatment was as follows: 27,896 (50.3%) lumpectomy with external beam radiation, 18,356 (33.1%) mastectomy alone, 6159 (11.1%) lumpectomy alone, 1488 (2.7%) mastectomy with reconstruction, and 1455 (2.6%) lumpectomy with brachytherapy (Table 1) .
Trends in local therapy
During the study interval, the proportion of patients undergoing mastectomy alone declined from 39.0% in 2000 to 28.2% in 2008 , and the use of breast conserving local therapies rose from 58.7% to 68.2% (Fig. 1A) . Specifically, lumpectomy plus external radiation rose from 47.9% in 2000 to a peak of 52.6% in 2003 before declining modestly to 50.4% of cases in 2008. This later decline was accompanied by a rise in breast conservation using brachytherapy. This strategy increased from fewer than 0.3% of cases in 2000 and 2001 to 6.1% of cases in 2008, which represented the fastest growth among all treatment options. Mastectomy followed by reconstruction accounted for 2.2% of cases in 2000 and 3.6% of cases in 2008, with most of this increase occurring during the final 2 years of the interval. Finally, the use of lumpectomy alone rose slightly, from 10.6% to 11.7% of cases during the study period.
When limited to only those patients for whom all of these treatments are considered guideline concordant (ie, age !70, stage T1N0, ERþ), similar trends in local therapy strategies were observed, with the exception that there was a much more pronounced increase in the use of lumpectomy alone, with the percentage of patients treated with this strategy stable between 2000 and 2003 at 12.9%, then (Fig. 1B) .
Predictors of treatment
Polychotomous logistic regression using lumpectomy plus external radiation as the referent was used to identify predictors for the use of the other 4 treatment strategies ( Table 2 ). The youngest patients and those with minimal comorbidities were more likely to undergo mastectomy with reconstruction. By contrast, older patients and those with more comorbidities were more likely to undergo shorter treatment strategies such as mastectomy alone, lumpectomy alone, or lumpectomy with brachytherapy. Additionally, lumpectomy with brachytherapy was strongly associated with a later year of diagnosis and with tumor features including smaller size, lower grade, ER positivity, node negativity, and ductal rather than lobular histology. Socioeconomic factors also correlated with treatment (Table 2) . One notable finding was a correlation between regions with low incomes or rural settings and the use of mastectomy alone.
Cost of treatment
For the year 2008, the median total costs for each treatment strategy, from highest to lowest, were ranked as follows: lumpectomy with brachytherapy ($36,749), mastectomy with reconstruction ($35,030), lumpectomy with external beam radiation ($31,388), mastectomy alone ($21,993), and lumpectomy alone ($19,287). The majority of costs were accrued during the treatment phase (0-6 months after diagnosis) regardless of the chosen therapy ( Figs. 2A and  2B ). However, qualitative differences were preserved during the period associated with managing adverse events (6-24 months), with combination therapies attendant with higher costs (Fig. 2C) . The cost of all treatment strategies grew at a rate faster than inflation, with the exception of lumpectomy with brachytherapy, whose cost was stable over time (Fig. 3 ).
Discussion
We used the SEER-Medicare database to characterize trends in local therapy and associated costs for older women with early-stage breast cancer diagnosed between 2000 and 2008 in the SEER-Medicare cohort. The main trend we observed was a steady decline in the use of mastectomy alone during this time frame, with increasing use of breast conserving strategies, particularly driven by the increasing use of lumpectomy with brachytherapy and lumpectomy alone. Although lumpectomy with brachytherapy was the most costly intervention before 2007, its inflation-adjusted cost was roughly stable over time, in contrast to the other strategies, whose growth in cost regularly exceeded inflation. The groundbreaking National Surgical Adjuvant Breast and Bowel Project B-6 study demonstrated that patients with diagnoses of with early-stage breast cancer had statistically equivalent survival whether they were treated with mastectomy or lumpectomy followed by adjuvant radiation (19) . After the study's publication in 1985, a steady rise in breast conservation was observed in the United States (20) (21) (22) . The patients benefited from less extensive surgeries requiring shorter hospital stays, fewer operative adverse events, and likely better cosmetic outcomes. The costs during this era were comparable between the 2 approaches because savings from reduced length of hospitalization and faster surgical recovery were offset by the cost of radiation therapy among those who underwent breast conservation (23, 24) .
In 2004, 2 landmark randomized clinical trials were published that sought to evaluate the need for whole breast irradiation specifically in older women with stage I ERpositive breast cancer (25, 26) . These studies found that whole breast irradiation conferred a small (<5%) absolute reduction in risk of local recurrence at 5 years for older women, without an accompanying benefit in overall breast preservation or survival. The entry criteria for 1 of these trials, the Cancer and Leukemia Group B (CALGB) 9343, were subsequently incorporated into the National Comprehensive Cancer Network guidelines to define a group of older patients for whom radiation could be omitted (27) , specifically women age !70 with clinical T1 N0, ERpositive disease resected with negative margins. Omission of radiation continues to be debated, however, with some experts arguing that the modest local control benefit conferred by radiation may justify its use for older patients with longer life expectancy (28) .
Yet, despite the research demonstrating the safety of breast conservation, by the 2000s the trend favoring adoption of breast conservation reversed in several singleinstitution and population-based studies (5-9). The reasons for the renewed popularity of mastectomy were unclear, but possibilities included better techniques for breast reconstruction and improved access to reconstruction after the passage of the Women's Health and Cancer Rights Act in 1998 (29) . Psychological factors favoring mastectomy may have included patients' anxieties over the malignant potential of residual breast tissue and the carcinogenicity of radiation. Advances in breast imaging, including the widespread use of breast magnetic resonance imaging, may also have contributed to these concerns (30) . Finally, the logistics of conventional radiation therapy, which requires 6 weeks of therapy, may have steered some patients to shorter interventions (31) .
By contrast, among the older Medicare population, we identified a trend in the opposite direction, with an 11% decline in the proportion of patients opting for mastectomy alone accompanied by a 10% rise in use of breast conserving strategies. This finding is similar to recent analyses by the National Cancer Database (32) and the SEERMedicare database (33) . A unique contribution of this report, however, is the incorporation of data about the use of breast reconstruction after mastectomy and the accompanying cost data. For example, our data indicate that for each patient who chooses lumpectomy plus external beam radiation over mastectomy plus reconstruction, approximately $3600 is saved. This vital information serves as an important reminder of the practical benefits of organ preservation facilitated by radiation. Notably, we did observe shifts over time in the relative proportions of the different breast conservation strategies used in the community. Breast conservation using external beam radiation declined modestly after 2003 in favor of strategies using lumpectomy alone or brachytherapy. The use of lumpectomy alone rose markedly after 2004, especially among favorable-risk patients who fit the CALGB 9343 entry criteria (25) . This observation is in accordance with a prior study by Soulos et al (34) , which also reported a modest trend toward the omission of radiation after the CALGB trial was published. However, another unique finding of the current study is that brachytherapy also rose significantly after 2004 among favorable-risk patients (Fig. 1B) . This suggests that some practitioners, rather than omit radiation, may have instead selected brachytherapy, perhaps in an effort to garner the local control benefits of radiation while avoiding the toxicities and inconvenience of whole breast treatment.
In the larger cohort of patients not limited by CALGB criteria, there was also observed a movement in favor of breast brachytherapy in later years that appeared to be at the expense of external radiation (Fig. 1A) . The time and effort required of the patient for several weeks of traditional external radiation therapy and its inferior reimbursement relative to brachytherapy may have influenced the adoption of the latter after its approval for use in the United States by the FDA.
Our second objective was to determine predictors of treatment strategy. We found that the youngest patients and those with the least comorbidities were more likely to receive mastectomy with reconstruction, echoing the findings of previously published studies that examined younger cohorts (5-9). We also found that patients with the least aggressive tumors (smaller size, lower grade, ER-positive, node-negative) were the most likely to undergo brachytherapy instead of conventional radiation, which may factors signifying lower socioeconomic status such as low area-level income and rural residence were associated with the use of mastectomy alone in lieu of combination strategies using radiation or reconstruction. This finding reiterates an oft-described failure in the United States to diffuse innovations in breast cancer care to the least advantaged (37) (38) (39) .
Month after Diagnosis Median
Our third objective was to examine the costs of these treatments. Lumpectomy plus brachytherapy was associated with the highest cost. However, an examination of trends revealed that brachytherapy exhibited a stable cost during the study period, in contrast to other treatments, whose cost curves consistently exceeded inflation. The relative stability in the cost of brachytherapy may be attributable to predictable Medicare fee schedules and a limited number of procedure codes. Declines in reimbursement for brachytherapy may have also offset inflationary trends. By contrast, the costs associated with lumpectomy and conventionally delivered radiation grew at a rate exceeding that of inflation. This trend is likely due to the adoption of 3-dimensional conformal and intensity modulated radiation techniques over the study period (40, 41) . In the future, the cost curve for external beam radiation may more closely track with inflation as a result of bundled payments prompted by the Accountable Care Act and the publication of convincing studies supporting the use of hypofractionation in postmenopausal women (41) (42) (43) .
This highlights a larger point: policymakers, payers, and physicians can control costs by promoting payment structures that encourage high-value interventions such as hypofractionation (44) . For example, a potential policy intervention based on this data would be to develop a bundle for local therapy for older women with early breast cancer amenable to breast conserving therapy. Setting a price point comparable to the cost of lumpectomy plus hypofractionated whole breast irradiation in patients with life expectancies longer than 10 years could incentivize this high-value treatment while discouraging more expensive treatment. Setting a price point comparable to lumpectomy alone in patients with life expectancy less than 10 years and ER-positive disease could incentivize this high value treatment in patients unlikely to benefit from radiation. Importantly, the use of qualifiers such as life expectancy or other pertinent characteristics can help ensure that bundled payments do not fail to account for meaningful differences among individual patients.
We used a combination of SEER data plus Medicare billing claims to classify treatments, thereby reducing the likelihood of misclassification bias in comparison with studies that rely only on SEER coding (45, 46) . Nevertheless, our study has certain limitations. First, the study cohort was limited to fee-for-service Medicare patients and may not generalize to younger patients or those covered by private insurance. Second, our cost analysis measured only expenses for which claims data were available. It did not include lost work time or discretionary health care expenses. Third, the period of time studied for cost calculations captured treatment-related costs and the costs of adverse events over the medium term. Inasmuch as differences in disease-free survival emerge later in the course of treated early-stage breast cancer, it is possible that expenses attributable to salvage therapy could change the relative cost profiles observed in our study. The cost of salvage therapy is expected to approximate the initial costs of therapy; for example, cost of salvage mastectomy is likely to be similar to the cost of mastectomy alone. However, because the risk of local recurrence is low, and the difference in local recurrence risk between treatments is small (4, 26) , the overall impact of salvage therapies on cost differences is expected to be minimal. Fourth, claims for external beam partial breast irradiation are indistinguishable from claims for whole breast irradiation, and thus we did not attempt to distinguish between these 2 treatments. However, other studies indicate that the use of external beam partial breast irradiation was quite low during this time interval, and thus our findings regarding lumpectomy followed by external beam radiation likely primarily reflect the experience with delivering whole breast irradiation. Fifth, the costs of endocrine therapy were not included and can vary widely, from as little as $600 for 5 years of tamoxifen to as much as approximately $36,000 for 5 years of letrozole (47) . Notably, given the expense of aromatase inhibitors, hypofractionated radiation may be a higher-value alternative for patients at very low risk of distant recurrence, for whom the primary intent of adjuvant therapy is to improve local disease control in the breast (41, 48) . Finally, our discussion of value and bundled payments assumes that costs are defined by reimbursement dollars. Other models for calculating costs, such as time-driven activity-based costing, are also under investigation. Such diligence by health economists and policymakers is necessary in the creation of value-based payment models to ensure that those models benefit patients rather than deny needed care.
It is concluded that in this population-based cohort of older women with early breast cancer, the use of mastectomy decreased, accompanied by increases in breast conserving approaches, including both standard external beam radiation and newer treatment strategies such as lumpectomy with brachytherapy or lumpectomy alone. Although mastectomy with reconstruction has become more popular in younger women, it has not yet gained significant traction among the population studied here. Using the cost estimates provided in this report, price points for local therapy bundles can be constructed to incentivize treatment strategies that confer the highest value to patients.
